Medication Shortage Alert – Pamidronate Disodium Injection:
Anna Ryabets-Lienhard, DO, Drugs and Therapeutics Committee
Update 10/25/23: As of August-September, there has been a national shortage of pamidronate IV injection. The current reasons are due to Areva is no longer manufacturing the product, and Pfizer is experiencing ‘manufacturing delays’. Drug Shortage Detail: Pamidronate Disodium Injection (ashp.org); Pamidronate Disodium Injection Drug Shortage Notice – Drugs.com
Products Affected:
- Pamidronate disodium injection, Mylan Institutional (Viatris), 3 mg/mL, 10 mL vial, 1 count, NDC 67457-0430-10
- Pamidronate disodium injection, Mylan Institutional (Viatris), 9 mg/mL, 10 mL vial, 1 count, NDC 67457-0446-10
- Pamidronate disodium injection, Pfizer, 3 mg/mL, 10 mL vial, 1 count, NDC 61703-0324-18
- Pamidronate disodium injection, Pfizer, 6 mg/mL, 10 mL vial, 1 count, NDC 61703-0325-18
- Pamidronate disodium injection, Pfizer, 9 mg/mL, 10 mL vial, 1 count, NDC 61703-0326-18
Estimated Release:
- Pfizer has short-dated pamidronate disodium 3 mg/mL 10 mL vials available with an expiration date of February 2024. There 6 mg/mL 10 mL vials and 9 mg/mL 10 mL vials are on back order and the company estimates a release date of March 2024.
- Viatris has pamidronate disodium 3 mg/mL 10 mL vials and 9 mg/mL 10 mL vials on back order and the company estimates a release date of late-November 2023.
Posted in Drug Shortages